Atara Biotherapeutics, Inc.ATRANASDAQ
Loading
Year-over-year SG&A expense growth
Latest
-6.97%
↓ 572% vs avg
Percentile
P33
Within normal range
Streak
2 qtr
Consecutive growthRecovering
Average
1.48%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -6.97% |
| Q3 2025 | -33.02% |
| Q2 2025 | -48.28% |
| Q1 2025 | 21.56% |
| Q4 2024 | -9.41% |
| Q3 2024 | 16.93% |
| Q2 2024 | -19.81% |
| Q1 2024 | 6.98% |
| Q4 2023 | -15.18% |
| Q3 2023 | -8.16% |
| Q2 2023 | -3.87% |
| Q1 2023 | 41.19% |
| Q4 2022 | -48.08% |
| Q3 2022 | 0.59% |
| Q2 2022 | -8.55% |
| Q1 2022 | -5.71% |
| Q4 2021 | 9.91% |
| Q3 2021 | 2.33% |
| Q2 2021 | 9.35% |
| Q1 2021 | 30.34% |
| Q4 2020 | -8.23% |
| Q3 2020 | -9.54% |
| Q2 2020 | -3.79% |
| Q1 2020 | -5.65% |
| Q4 2019 | -5.04% |
| Q3 2019 | -18.32% |
| Q2 2019 | 21.13% |
| Q1 2019 | -1.73% |
| Q4 2018 | 15.99% |
| Q3 2018 | -12.33% |
| Q2 2018 | 37.48% |
| Q1 2018 | 26.84% |
| Q4 2017 | -0.28% |
| Q3 2017 | 15.07% |
| Q2 2017 | 11.52% |
| Q1 2017 | 63.26% |
| Q4 2016 | -26.05% |
| Q3 2016 | 9.95% |
| Q2 2016 | 11.70% |
| Q1 2016 | 4.96% |